iOrganBio, an innovator in intelligent cell manufacturing, announced the appointment of Lee L. Rubin, Ph.D., to its Scientific Advisory Board. Dr. Rubin is a leading authority in stem cell biology, regenerative medicine, and translational neuroscience, whose research has advanced the understanding of neurodegenerative diseases and contributed to the development of multiple therapeutic candidates. He is Co-Director and Principal Faculty of the Harvard Stem Cell Institute and Professor in Harvard’s Department of Stem Cell and Regenerative Biology.
Dr. Rubin’s pioneering work spans blood-brain barrier biology, neural stem cell differentiation, disease modeling using patient-derived induced pluripotent stem cells, and the discovery of therapeutic candidates for disorders including Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). His expertise will be key to expanding iOrganBio’s platform in neurological applications, leveraging the company’s CellForge platform that combines AI prediction, biological sensing, and automated 3D incubation to engineer human cells and organoids with greater precision and consistency.
“We are thrilled to welcome Dr. Rubin to our Scientific Advisory Board,” said the company in a statement. “His extensive academic and entrepreneurial leadership will be invaluable as we advance our mission to transform human cell production for disease modeling, drug discovery, and cell therapy development.”
iOrganBio’s CellForge platform is designed to produce cells and organoids at scale for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs). The platform uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles. At its core is the functional human CellAtlas™, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type.
The announcement highlights the growing importance of scalable, consistent cell manufacturing for neurological disease research. Dr. Rubin’s appointment signals iOrganBio’s commitment to advancing in vitro modeling and cell therapies for conditions that currently lack effective treatments. For more information, visit iOrgan.Bio or follow the company on LinkedIn.
